MX2020002303A - Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon. - Google Patents
Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon.Info
- Publication number
- MX2020002303A MX2020002303A MX2020002303A MX2020002303A MX2020002303A MX 2020002303 A MX2020002303 A MX 2020002303A MX 2020002303 A MX2020002303 A MX 2020002303A MX 2020002303 A MX2020002303 A MX 2020002303A MX 2020002303 A MX2020002303 A MX 2020002303A
- Authority
- MX
- Mexico
- Prior art keywords
- stimulator
- modulators
- nucleotides
- cyclic
- interferon genes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
Abstract
La presente descripción se refiere a un compuesto de las fórmulas (I) o (II), o una sal farmacéuticamente aceptable, un solvato, un hidrato de este, una composición farmacéutica que comprende un compuesto de las fórmulas (I) o (II), y uso de este, donde varios grupos de Markush son como se describen en la presente.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762552148P | 2017-08-30 | 2017-08-30 | |
US201862660565P | 2018-04-20 | 2018-04-20 | |
PCT/IB2018/056658 WO2019043634A2 (en) | 2017-08-30 | 2018-08-30 | CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020002303A true MX2020002303A (es) | 2020-09-10 |
Family
ID=65527221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002303A MX2020002303A (es) | 2017-08-30 | 2018-08-30 | Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon. |
Country Status (14)
Country | Link |
---|---|
US (1) | US11773132B2 (es) |
EP (1) | EP3692048A4 (es) |
JP (1) | JP7311514B2 (es) |
KR (1) | KR20200058411A (es) |
CN (1) | CN111263767B (es) |
AU (1) | AU2018323053A1 (es) |
BR (1) | BR112020004047A2 (es) |
CA (1) | CA3073919A1 (es) |
IL (1) | IL272928A (es) |
MX (1) | MX2020002303A (es) |
RU (1) | RU2020112502A (es) |
SG (1) | SG11202001847WA (es) |
TW (1) | TWI808092B (es) |
WO (1) | WO2019043634A2 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL280430B2 (en) | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
CA3053568A1 (en) | 2017-02-21 | 2018-08-30 | Board Of Regents, The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
WO2019043634A2 (en) | 2017-08-30 | 2019-03-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS |
US11542293B2 (en) | 2017-11-10 | 2023-01-03 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
KR20200130362A (ko) * | 2018-03-08 | 2020-11-18 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
BR112020024605A2 (pt) | 2018-06-01 | 2021-04-06 | Eisai R&D Management Co., Ltd. | Métodos para o tratamento de câncer de bexiga |
US11401295B2 (en) | 2018-10-12 | 2022-08-02 | Shanghai Jemincare Pharmaceuticals Co., Ltd. | Cyclic dinucleotide compound and uses thereof |
US20220251135A1 (en) * | 2019-07-25 | 2022-08-11 | Beigene, Ltd. | Cyclic dinucleotides as sting agonists |
EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | Ono Pharmaceutical Co | CANCER THERAPY METHODS |
CN111592570B (zh) * | 2020-05-15 | 2022-04-29 | 清华大学 | 新型sting激动剂及其制备方法和应用 |
US20240059729A1 (en) * | 2020-10-20 | 2024-02-22 | Tyligand Bioscience (Shanghai) Limited | Multifunctional cyclic dinucleotide and use thereof |
KR102466750B1 (ko) * | 2020-10-23 | 2022-11-15 | 아주대학교산학협력단 | 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물 |
MX2023005381A (es) | 2020-11-09 | 2023-05-23 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco. |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
AU2003291002A1 (en) | 2002-11-15 | 2004-06-15 | Chiron Corporation | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
WO2005005450A1 (ja) | 2003-07-15 | 2005-01-20 | Mitsui Chemicals, Inc. | 環状ビスジヌクレオシドの合成方法 |
EP1651242A2 (en) * | 2003-07-28 | 2006-05-03 | David K. R. Karaolis | Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation |
US7709458B2 (en) | 2004-03-15 | 2010-05-04 | David K. R. Karaolis | Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
ME00588A (en) | 2006-08-18 | 2011-12-20 | Prlr-specific antibody and uses thereof | |
ES2740823T3 (es) | 2008-01-15 | 2020-02-06 | Univ Leland Stanford Junior | Métodos para manipular fagocitosis mediada por CD47 |
EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
WO2009133560A1 (en) | 2008-04-29 | 2009-11-05 | Smart Assays | Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof |
EP2403528B1 (en) | 2009-03-02 | 2016-04-20 | Aduro Biotech Holdings, Europe B.V. | Antibodies against a proliferating inducing ligand (april) |
EA036314B1 (ru) | 2010-08-20 | 2020-10-26 | Новартис Аг | Выделенные антитела к рецептору эпидермального фактора роста-3 (her3) и их фрагменты, фармацевтическая композиция, содержащая эти антитела и фрагменты, и их применение для лечения рака |
WO2014093936A1 (en) | 2012-12-13 | 2014-06-19 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
BR112015027327B1 (pt) | 2013-04-29 | 2022-08-02 | Rutgers, The State University Of New Jersey | Composto, modulador de cgas, composição farmacêutica compreendendo o referido composto ou modulador |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
JP6453855B2 (ja) | 2013-05-18 | 2019-01-16 | アドゥロ バイオテック,インク. | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法 |
AU2014340269B2 (en) | 2013-10-21 | 2018-06-21 | Drexel University | Use of STING agonists to treat chronic hepatitis B virus infection |
WO2015074145A1 (en) | 2013-11-22 | 2015-05-28 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
JP6462006B2 (ja) | 2014-06-04 | 2019-01-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Stingのモジュレーターとしての環式ジヌクレオチド |
EP3233882B1 (en) | 2014-12-16 | 2019-10-30 | Kayla Therapeutics | Fluorinated cyclic dinucleotides for cytokine induction |
EP3233191A1 (en) | 2014-12-16 | 2017-10-25 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
GB201501462D0 (en) * | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
KR20170129802A (ko) * | 2015-03-10 | 2017-11-27 | 아두로 바이오테크, 인코포레이티드 | "인터페론 유전자의 자극인자"-의존적 신호전달을 활성화하는 조성물 및 방법 |
GEP20207182B (en) | 2015-08-13 | 2020-11-25 | Merck Sharp & Dohme | Cyclic di-nucleotide compounds as sting agonists |
AU2016343993A1 (en) | 2015-10-28 | 2018-05-10 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
MA52157A (fr) | 2015-12-03 | 2021-02-17 | Glaxosmithkline Ip Dev Ltd | Dinucléotides cycliques de purine utilisés comme modulateurs de sting |
WO2017106740A1 (en) * | 2015-12-16 | 2017-06-22 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production |
CN109451740B (zh) | 2016-01-11 | 2022-09-02 | 先天肿瘤免疫公司 | 用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸 |
WO2017123657A1 (en) | 2016-01-11 | 2017-07-20 | Gary Glick | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
IL280430B2 (en) * | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
WO2017186711A1 (en) * | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
WO2018045204A1 (en) | 2016-08-31 | 2018-03-08 | Ifm Therapeutics, Inc | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
US11001605B2 (en) * | 2016-10-07 | 2021-05-11 | Biolog Life Science Institute Gmbh & Co. Kg | Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways |
JOP20170188A1 (ar) * | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
US20200113924A1 (en) | 2016-12-20 | 2020-04-16 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
JP7295360B2 (ja) * | 2016-12-21 | 2023-06-21 | モナーク・バイオサイエンシズ・インコーポレイテッド | 固形腫瘍細胞及びエスケープバリアントを治療するための足場 |
WO2018138685A2 (en) | 2017-01-27 | 2018-08-02 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
JP7213188B2 (ja) | 2017-01-27 | 2023-01-26 | ヤンセン バイオテツク,インコーポレーテツド | Stingアゴニストとしての環状ジヌクレオチド |
WO2019043634A2 (en) | 2017-08-30 | 2019-03-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS |
US11401295B2 (en) * | 2018-10-12 | 2022-08-02 | Shanghai Jemincare Pharmaceuticals Co., Ltd. | Cyclic dinucleotide compound and uses thereof |
-
2018
- 2018-08-30 WO PCT/IB2018/056658 patent/WO2019043634A2/en unknown
- 2018-08-30 JP JP2020533876A patent/JP7311514B2/ja active Active
- 2018-08-30 EP EP18850228.0A patent/EP3692048A4/en active Pending
- 2018-08-30 RU RU2020112502A patent/RU2020112502A/ru unknown
- 2018-08-30 AU AU2018323053A patent/AU2018323053A1/en not_active Abandoned
- 2018-08-30 US US16/643,127 patent/US11773132B2/en active Active
- 2018-08-30 SG SG11202001847WA patent/SG11202001847WA/en unknown
- 2018-08-30 BR BR112020004047-9A patent/BR112020004047A2/pt not_active IP Right Cessation
- 2018-08-30 KR KR1020207008457A patent/KR20200058411A/ko not_active Application Discontinuation
- 2018-08-30 TW TW107130419A patent/TWI808092B/zh active
- 2018-08-30 MX MX2020002303A patent/MX2020002303A/es unknown
- 2018-08-30 CN CN201880056293.1A patent/CN111263767B/zh active Active
- 2018-08-30 CA CA3073919A patent/CA3073919A1/en not_active Abandoned
-
2020
- 2020-02-26 IL IL272928A patent/IL272928A/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202001847WA (en) | 2020-03-30 |
RU2020112502A (ru) | 2021-10-01 |
WO2019043634A3 (en) | 2019-04-11 |
JP2020532585A (ja) | 2020-11-12 |
CN111263767B (zh) | 2023-07-18 |
US20200331957A1 (en) | 2020-10-22 |
TW201919650A (zh) | 2019-06-01 |
AU2018323053A1 (en) | 2020-03-19 |
CN111263767A (zh) | 2020-06-09 |
EP3692048A4 (en) | 2021-10-20 |
US11773132B2 (en) | 2023-10-03 |
CA3073919A1 (en) | 2019-03-07 |
TWI808092B (zh) | 2023-07-11 |
JP7311514B2 (ja) | 2023-07-19 |
IL272928A (en) | 2020-04-30 |
BR112020004047A2 (pt) | 2020-09-01 |
KR20200058411A (ko) | 2020-05-27 |
EP3692048A2 (en) | 2020-08-12 |
RU2020112502A3 (es) | 2021-10-08 |
WO2019043634A2 (en) | 2019-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020002303A (es) | Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon. | |
PH12016502318A1 (en) | Cyclic di-nucleotides as modulators of sting | |
MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
PH12018500904A1 (en) | Peptide macrocycles against acinetobacter baumannii | |
PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
MY196749A (en) | Eif4a-inhibiting compounds and methods related thereto | |
PH12019500579A1 (en) | Pharmaceutical composition | |
AU2018253590A1 (en) | Imidazopyridazine compounds | |
PH12020551486A1 (en) | Cyclopentane-based modulators of sting (stimulator of interferon genes) | |
PH12018500377A1 (en) | Novel annelated benzamides | |
PH12018500378B1 (en) | Novel annelated phenoxyacetamides | |
PH12017501280B1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
MY181641A (en) | Amino pyran ring derivative and composition and use thereof | |
MX2017009292A (es) | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. | |
MX2021015188A (es) | Moduladores de nueva generacion del estimulador de genes de interferon (sting). | |
MX2022003633A (es) | Moduladores poliheterociclicos de sting (estimulador de genes de interferon). | |
MX2018008153A (es) | Derivados de c-glicósido que tienen anillos de fenilo condensado o sales farmacéuticamente aceptables de los mismos, metodo para prepararlos y composición farmacéutica que los contiene. |